Osteomielitis

01Pathophysiology

Osteomyelitis is an infection of bone that can arise through three distinct routes: hematogenous spread, contiguous spread from adjacent soft tissue, or direct inoculation from trauma or surgery.

In hematogenous osteomyelitis, bacteria seed the bone via the bloodstream. In children, this preferentially affects the metaphysis of long bones (distal femur, proximal tibia) because the sluggish, tortuous blood flow through metaphyseal capillary loops creates a favorable environment for bacterial trapping and proliferation. The terminal arterioles in the metaphysis lack phagocytic lining cells, which means bacteria can settle and multiply with less immune opposition. This explains why a child with hematogenous osteomyelitis presents with focal metaphyseal tenderness, fever, and refusal to use the limb.

In adults, hematogenous osteomyelitis most commonly affects the vertebral bodies. The vertebral endplates have a rich arterial blood supply, and bacteremia (e.g., from endocarditis, urinary tract infection, or IV drug use) can deliver organisms directly to this vascular bed. The infection typically involves two adjacent vertebral bodies and the intervening disc space, a pattern that helps distinguish it from malignancy on imaging.

Contiguous-focus osteomyelitis results from direct extension of infection from overlying soft tissue. The classic scenario is a diabetic foot ulcer that penetrates through skin, subcutaneous tissue, and periosteum to reach bone. Peripheral neuropathy prevents the patient from sensing tissue damage, and peripheral vascular disease impairs local immune responses, creating a perfect environment for deep infection. This is why diabetic patients with chronic, non-healing ulcers are at such high risk.

Once bacteria reach bone, they trigger an acute inflammatory response that increases intraosseous pressure. This elevated pressure compromises the periosteal and endosteal blood supply, leading to ischemic necrosis of bone. Dead bone segments, called sequestra, become avascular islands that antibiotics cannot penetrate and that the immune system cannot clear. In chronic osteomyelitis, the periosteum lays down reactive new bone called the involucrum, which encases the sequestrum. A cloaca (an opening in the involucrum) may form, creating a draining sinus tract to the skin surface. These pathologic features are frequently referenced in imaging-based questions.

02Classification and Clinical Manifestation

Waldvogel Classification (by pathogenesis)

Cierny-Mader Classification (by anatomy and host status)

Clinical Manifestation by Duration

03Diagnostic Workup

The workup begins with clinical suspicion. In a patient with focal bone pain, fever, and risk factors, the best initial step is to obtain plain radiographs along with inflammatory markers (ESR and CRP) and blood cultures. Plain films are often normal early in the disease course because at least 30 to 50% of bone mineral content must be lost before lytic changes become visible on X-ray. However, they are still ordered first to rule out fractures, malignancy, or other bony pathology.

When plain films are normal or equivocal but clinical suspicion remains high, the next step is MRI. This is the most accurate imaging modality for osteomyelitis. MRI excels at detecting early bone marrow edema before cortical destruction occurs, defining the anatomic extent of infection, and identifying complications such as subperiosteal or soft tissue abscesses. On MRI, infected bone shows low signal on T1-weighted images (because normal fatty marrow is replaced by edema and inflammatory cells) and high signal on T2-weighted and STIR sequences. Gadolinium enhancement shows rim-enhancing abscesses and areas of active inflammation.

If MRI is contraindicated (e.g., certain implanted devices) or produces significant artifact from orthopedic hardware, a triple-phase bone scan is the alternative. The bone scan is highly sensitive but less anatomically precise. A tagged WBC scan can be added for improved differentiation between infection and non-infectious inflammatory processes, particularly in chronic cases or in the presence of prior surgery.

The gold standard for diagnosis is bone biopsy with culture and histopathology. This is the only test that provides definitive organism identification and antibiotic susceptibility data. In cases of vertebral osteomyelitis, a CT-guided needle biopsy is typically performed. In diabetic foot infections, intraoperative bone specimens obtained during surgical debridement serve the same purpose. It is important to obtain bone cultures before starting empiric antibiotics whenever clinically feasible, as prior antibiotic exposure can sterilize cultures and leave the clinician guessing about the pathogen.

For diabetic foot ulcers, the probe-to-bone test is a rapid bedside screening tool. If a blunt sterile probe inserted into the ulcer reaches bone, the test is considered positive and has high predictive value for underlying osteomyelitis, particularly in patients with a high pretest probability.

04Management and Treatment

Acute Stabilization

The first priority is hemodynamic stabilization and blood cultures. In a patient who is septic or hemodynamically unstable, do not delay antibiotics for biopsy. Start empiric IV therapy immediately. However, in a stable patient with suspected vertebral osteomyelitis who has not yet had a tissue diagnosis, it is preferable to obtain bone biopsy before starting antibiotics to maximize culture yield.

Empiric therapy should cover the most likely organisms. In most clinical scenarios, this means vancomycin (for MRSA coverage) combined with a broad-spectrum beta-lactam such as piperacillin-tazobactam or a third-generation cephalosporin. Once culture and sensitivity results are available, therapy should be narrowed. This de-escalation principle is a commonly tested concept.

For MSSA-confirmed infections, the treatment of choice is nafcillin, oxacillin, or cefazolin rather than vancomycin. Vancomycin is inferior to anti-staphylococcal penicillins for MSSA due to slower bactericidal activity. This is a frequently tested point: once MSSA is confirmed, do not continue vancomycin.

Duration and Monitoring

Standard treatment duration for osteomyelitis is 4 to 6 weeks of IV antibiotics. Response to therapy is monitored clinically and with serial CRP levels. CRP typically normalizes within 1 to 2 weeks of effective therapy; a persistently elevated or rising CRP should prompt re-evaluation for treatment failure, undrained abscess, or resistant organisms. ESR declines more slowly and is less useful for short-term monitoring.

Surgical Intervention

Surgery is indicated for:

• Chronic osteomyelitis with sequestrum formation (dead bone that antibiotics cannot penetrate)

• Epidural abscess complicating vertebral osteomyelitis (neurosurgical emergency if neurologic deficits are present)

• Failed medical therapy (persistent bacteremia, worsening symptoms despite appropriate antibiotics)

• Infected orthopedic hardware (removal of hardware is often necessary for cure)

• Diabetic foot osteomyelitis not responding to antibiotics alone (debridement or partial amputation)

In chronic osteomyelitis, antibiotics alone are rarely curative without surgical debridement of necrotic bone. This is because the sequestrum is avascular and acts as a nidus for persistent infection. Surgery removes dead tissue and improves antibiotic penetration into viable bone.

Contraindications and Adjustments

• In renal insufficiency, vancomycin requires dose adjustment guided by trough levels and/or AUC monitoring.

• Fluoroquinolones (ciprofloxacin, levofloxacin) should be avoided in children due to risk of cartilage damage, except in selected cases (e.g., Salmonella osteomyelitis where benefits outweigh risks).

• In penicillin-allergic patients with MSSA, cefazolin can often be used (cross-reactivity is low). For severe penicillin allergy, vancomycin or daptomycin are alternatives.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common trap with osteomyelitis questions is over-relying on plain radiographs to rule out the diagnosis. Test-writers love to present a patient with 5 to 7 days of progressive bone pain and fever, show you a normal X-ray, and then ask for the next step. The wrong answer is "reassurance" or "repeat X-ray in 2 weeks." The right answer is MRI, because radiographic changes lag behind the actual disease process by 10 to 14 days.

Another high-frequency trap involves sickle cell disease. The classic teaching is that Salmonella is the most common cause of osteomyelitis in sickle cell patients, and this association is heavily tested. However, be careful: while Salmonella is the most commonly tested organism in this context, some question stems will test whether you know that S. aureus is still the most common organism overall, even in sickle cell disease. Read the question carefully to determine whether it is asking for the "most common" versus the "most characteristic" or "most likely on the exam."

A third trap concerns vertebral osteomyelitis in an IV drug user. These patients present with insidious back pain and low-grade fever. Many students jump to discitis alone or mechanical back pain. The key is recognizing that hematogenous vertebral osteomyelitis should be suspected in any IV drug user, post-procedural patient, or elderly patient with new back pain and fever, and MRI of the spine is the appropriate imaging study.

In diabetic foot osteomyelitis, a commonly tested pearl is the probe-to-bone test. If the vignette describes a deep ulcer in a diabetic foot and a probe reaches bone, the answer is osteomyelitis until proven otherwise, and the next step is MRI to confirm extent, followed by bone biopsy and culture to identify organisms and guide antibiotic selection.

Finally, remember the management hierarchy: bone biopsy before antibiotics in stable patients (to avoid sterilizing cultures), vancomycin for empiric MRSA coverage (but switch to nafcillin/cefazolin once MSSA is confirmed), 4 to 6 weeks of IV therapy, and surgical debridement is essential for chronic osteomyelitis because antibiotics cannot penetrate dead bone. The core competency being tested across osteomyelitis questions is the ability to sequence diagnostics correctly (labs, imaging, biopsy) and match the organism to the clinical context.